Publicaciones en colaboración con investigadores/as de Universitat Autònoma de Barcelona (14)

2023

  1. Cardiac Fibrosis in heart failure: Focus on non-invasive diagnosis and emerging therapeutic strategies

    Molecular Aspects of Medicine, Vol. 93

  2. Prediction of Left Ventricular Reverse Remodeling and Outcomes by Circulating Collagen-Derived Peptides

    JACC: Heart Failure, Vol. 11, Núm. 1, pp. 58-72

2022

  1. A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy

    Cancers, Vol. 14, Núm. 12

  2. Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

    European Journal of Heart Failure, Vol. 24, Núm. 6, pp. 927-943

  3. Cardiac remodelling – Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

    European Journal of Heart Failure, Vol. 24, Núm. 6, pp. 944-958

  4. Long-Term Prognostic Impact of Estimated Glomerular Filtration Rate on Admission in Patients Hospitalized for Acute Heart Failure

    CardioRenal Medicine, Vol. 12, Núm. 4, pp. 179-188

  5. Transition to heart failure in hypertension: going to the heart of the matter

    European heart journal

2021

  1. Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review

    Frontiers in Cardiovascular Medicine, Vol. 8

2020

  1. Cardiorenal interaction and heart failure outcomes. A role for insulin-like growth factor binding protein 2?

    Revista Espanola de Cardiologia, Vol. 73, Núm. 10, pp. 835-843

  2. Myocardial interstitial fibrosis in the era of precision medicine. Biomarker-based phenotyping for a personalized treatment

    Revista Espanola de Cardiologia, Vol. 73, Núm. 3, pp. 248-254

2018

  1. Myocardial remodeling in hypertension toward a new view of hypertensive heart disease

    Hypertension, Vol. 72, Núm. 3, pp. 549-558

  2. Transitioning fromusual care to biomarkerbased personalized and precisionmedicine in heart failure: Call for action

    European Heart Journal, Vol. 39, Núm. 30, pp. 2793-2798

2017

  1. Compelling benefit of soluble suppression of tumorigenicity-2 in post-myocardial infarction estimation of risk: The time is right for its routine use in the clinic

    Journal of the American Heart Association

2009

  1. TORAFIC study protocol: Torasemide prolonged release versus furosemide in patients with chronic heart failure

    Expert Review of Cardiovascular Therapy, Vol. 7, Núm. 8, pp. 897-904